Amsterdam

• A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting
  2023-505221-14-00 4 2024-04-04 Multiple Myeloma
• A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting
  2023-506759-51-00 7 2024-03-29 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• An Open-Label Exploratory Study of Fosigotifator in Subjects with Vanishing White Matter Disease Recruiting
  2023-505704-30-00 9 2024-03-22 Vanishing White Matter disease
• Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associate … Recruiting
  2023-505933-29-00 4 2024-03-13 IgM monoclonal gammopathy of unknown significance (MGUS) and myelin as
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock f … Recruiting
  2024-510892-40-00 6 2024-02-29 Acute myocardial infarction complicated by cardiogenic shock
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancer Recruiting
  2022-501818-54-00 3 2024-02-22 Small cell lung carcinoma (SCLC)
• A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting
  2023-507460-39-00 10 2024-02-15 Adult patients with resectable muscle-invasive urothelial cancer of th
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 Triple negative breast cancer
• PREMI trial Recruiting
  2023-503220-76-01 6 2024-02-13 Unexplained recurrent miscarriages
• Ph1/2 study of AVB-101 in Subjects with Frontotemporal Dementia with Progranulin Mutations (FTD-GRN) Recruiting
  2023-509444-10-00 7 2024-02-08 Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol … Recruiting
  2023-506698-36-00 5 2024-02-02 low-volume metastatic castration-sensitive prostate cancer
• Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS) Recruiting
  2023-505756-21-00 4 2024-01-26 dMMR tumors consisting of but not limited to; Colorectal cancer, oesop
• A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emis … Recruiting
  2023-506971-89-00 5 2024-01-25 Coronary Artery Disease
• A study to investigate the effect of adding cobicistat to venetoclax and azacitidine in patients with acute myeloid leukemia (AML) who are i … Recruiting
  2023-505379-61-00 4 2024-01-17 Acute Myeloid Leukaemia
• PEHAB II Recruiting
  2023-507466-40-00 6 2024-01-12 Prostate cancer
• Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULC … Recruiting
  2022-502685-25-00 10 2024-01-01 The trial population will consist of patients with LAVC who require pr
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 Breast Cancer; Advanced solid tumors including but not limited to gyne
• Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n … Recruiting
  2023-504637-42-01 6 2023-12-21 aortic valve stenosis
• A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma Recruiting
  2022-502984-39-00 5 2023-12-13 Severe Uncontrolled Asthma Asthma (an illness that causes breathing di
• Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 study Recruiting
  2024-518192-61-00 9 2023-12-08 Breast cancer
• Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in … Recruiting
  2023-504351-26-01 11 2023-12-06 Pulmonary arterial hypertension (group I)

Showing 505–528 of 1,112 trials